Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases. Issue 10 (1st July 2022)

• Record Type: Journal Article
• Authors: Ramasubramanian, Lalithasri; Du, Shixian; Gidda, Siraj; Bahatyrevich, Nataliya; Hao, Dake; Kumar, Priyadarsini; Wang, Aijun
• Is Part Of: Advanced biology. Volume 6:Issue 10(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-01
• Subjects: extracellular vesicles -- cardiovascular disease -- cargo loading -- nanotherapeutics -- targeted delivery; Molecular biology -- Periodicals; Systems biology -- Periodicals; Biological systems -- Periodicals; Biotechnology -- Periodicals; Bioengineering -- Periodicals; Biomedical engineering -- Periodicals; 660.6
• DOI: 10.1002/adbi.202200087
• Languages: English
• ISSNs: 2701-0198

Abstract

Abstract: Cardiovascular diseases (CVD) remain one of the leading causes of mortality worldwide. Despite recent advances in diagnosis and interventions, there is still a crucial need for new multifaceted therapeutics that can address the complicated pathophysiological mechanisms driving CVD. Extracellular vesicles (EVs) are nanovesicles that are secreted by all types of cells to transport molecular cargo and regulate intracellular communication. EVs represent a growing field of nanotheranostics that can be leveraged as diagnostic biomarkers for the early detection of CVD and as targeted drug delivery vesicles to promote cardiovascular repair and recovery. Though a promising tool for CVD therapy, the clinical application of EVs is limited by the inherent challenges in EV isolation, standardization, and delivery. Hence, this review will present the therapeutic potential of EVs and introduce bioengineering strategies that augment their natural functions in CVD. Abstract : Extracellular vesicles (EVs) are membrane‐bound nanovesicles secreted by cells to mediate biological functions. In the cardiovascular system, EVs maintain homeostasis and promote repair mechanisms following cardiovascular diseases onset. However, poor standardization and targeting specificity challenge the clinical potential of EV therapy. New bioengineering strategies have been developed to augment the natural bioactive properties of EVs and enhance therapeutic efficacy.